Construction of LP-LNP with novel lipopeptides as adjuvants and its enhancing effects on mRNA vaccines

Jingwen CAO; Yu CHI; Guocheng LI; Hao CHENG; Yan DENG; Jing WEI; Ji ZHU; Yingying GAO; Haibo LI

doi:10.16016/j.2097-0927.202402048

您当前的位置：

首页 >

文章列表页 >

Construction of LP-LNP with novel lipopeptides as adjuvants and its enhancing effects on mRNA vaccines

Basic Medicine | 更新时间：2026-01-09

- Construction of LP-LNP with novel lipopeptides as adjuvants and its enhancing effects on mRNA vaccines
- Journal of Army Medical University Vol. 46, Issue 17, Pages: 1925-1933(2024)
- 作者机构：
  
  1.154007 黑龙江佳木斯，佳木斯大学临床医学院
  2.400038 重庆，陆军军医大学(第三军医大学)药学与检验医学系微生物与生化药学教研室，国家免疫生物制品工程技术研究中心
  3.401320 重庆，重庆医科大学附属巴南医院检验科
- 作者简介：
- 基金信息：
  
  the General Program of National Natural Science Foundation of China(32270988);the Key Project of Natural Science Foundation of Chongqing(cstc2020jcyj-zdxmX0027)
- DOI：10.16016/j.2097-0927.202402048
  CLC： R342.22;R914.2;R979.5
- Received：19 February 2024，
  
  Revised：2024-04-16，
  
  Published：15 September 2024
- 稿件说明：
移动端阅览
Jingwen CAO, Yu CHI, Guocheng LI, et al. Construction of LP-LNP with novel lipopeptides as adjuvants and its enhancing effects on mRNA vaccines[J]. Journal of Army Medical University, 2024, 46(17): 1925-1933.
DOI：

Jingwen CAO, Yu CHI, Guocheng LI, et al. Construction of LP-LNP with novel lipopeptides as adjuvants and its enhancing effects on mRNA vaccines[J]. Journal of Army Medical University, 2024, 46(17): 1925-1933. DOI： 10.16016/j.2097-0927.202402048.

摘要

目的

构建以新型脂肽为佐剂的递送系统脂肽-脂质纳米颗粒(lipopeptide-lipid nanoparticle，LP-LNP)，初步探究其对mRNA疫苗的增效作用。

方法

设计并合成2种新型脂肽SS-10和SQ18，微流控技术将编码增强型绿色荧光蛋白(enhanced green fluorescent protein，eGFP)、萤火虫荧光素酶(firefly luciferase，F-luc)和卵清白蛋白(ovalbumin，OVA)的mRNA包载到LP-LNP中，构建以新型脂肽为佐剂的mRNA递送系统；利用动态光散射法表征LP-LNP的粒径、多分散系数；利用HEK-Blue

mTLR2报告细胞检测其Toll样受体2(Toll-like receptors 2

TLR2)的激活作用，筛选最优脂肽掺入比；将优选的LP-LNP-eGFP-mRNA转染至HEK293T细胞，荧光显微镜观察eGFP的表达；利用活体成像技术考察LP-LNP-F-luc-mRNA在小鼠体内的表达水平；流式细胞术评价LP-LNP-OVA-mRNA免疫小鼠后诱导引流淋巴结中树突状细胞(dendritic cells，DCs)成熟水平以及交叉递呈抗原的能力。

结果

脂肽SQ18和SS-10分别以0.50%、0.75%的摩尔比掺入后，得到的LP-LNP平均粒径分别为127和121 nm，平均多分散系数分别为0.11和0.08，包封率均在90%以上，且体外安全性好；该配方条件下激活TLR2的能力显著强于阳性对照Pam

CSK

(

＜0.01)；优选的LP-LNP均可以实现有效的体外转染，其中SQ18以0.50%掺入制备的LP-LNP体内转染效果显著优于传统LNP(

＜0.01)，且可以显著促进引流淋巴结DCs的成熟以及抗原的交叉递呈(

＜0.05)。

结论

以新型脂肽为佐剂的LP-LNP可以增强mRNA的递送能力，进一步提高mRNA疫苗的免疫效果。

Abstract

Objective

To construct lipid nanoparticles (lipopeptide-lipid nanoparticle

LP-LNP) with novel lipopeptides as adjuvants

and initially explore their synergistic effect on mRNA vaccines.

Methods

Two novel lipopeptides

SS-10 and SQ18

were designed and synthesized. Microfluidic technology was used to encapsulate lipopeptides in differ

ent proportions

as well as mRNAs encoding enhanced green fluorescent protein (eGFP)

firefly luciferase (F-luc)

and ovalbumin (OVA) into lipid nanoparticles to construct an mRNA delivery system with novel lipopeptides as adjuvants (LP-LNP). The particle size and polydispersity coefficient of LP-LNP were measured using dynamic light scattering. The activation effect on Toll-like receptors 2 (TLR2) was detected using HEK-Blue

mTLR2 reporter cells to screen the optimal lipopeptide ratio. The preferred LP-LNP-eGFP-mRNA was transfected into HEK293T cells

and the expression of eGFP was observed under a fluorescence microscope.

In vivo

imaging was used to investigate the expression level of LP-LNP-F-luc-mRNA in mice. Flow cytometry was used to evaluate the ability of LP-LNP-OVA-mRNA to induce the maturation of dendritic cells (DCs) in draining lymph nodes and cross-presentation of antigens after immunization.

Results

Lipopeptides SQ18 and SS-10 were incorporated into LNP at 0.50% and 0.75% molar ratios

respectively

to obtain LP-LNP with uniform particle size

high encapsulation efficiency

and good

in vitro

safety. The ability of this formulation to activate TLR2 was significantly stronger than the positive control Pam

CSK

(

0.01). The preferred LP-LNP obtained effective

in vitro

transfection

and LP-LNP prepared with SQ18 at 0.50% molar ratio had significantly better

in vivo

transfection efficiency than traditional LNP (

0.01)

and significantly promoted the maturation of DCs in draining lymph nodes and cross-presentation of antigens (

0.05).

Conclusion

LP-LNP with novel lipopeptides as adjuvants can enhance the delivery capacity of mRNA and further improve the immune effect of mRNA vaccines.

关键词

Keywords

references

XIE C Y, YAO R H, XIA X J. The advances of adjuvants in mRNA vaccines[J]. NPJ Vaccines, 2023, 8: 162. DOI: 10.1038/s41541-023-00760-5.

WANG Y, ZHANG Z Q, LUO J W, et al . mRNA vaccine: a potential therapeutic strategy[J ] . Mol Cancer, 2021, 20(1): 33. DOI: 10.1186/s12943-021-01311-z.

PARDI N, HOGAN M J, PORTER F W, et al . mRNA vaccines —a new era in vaccinology[J ] . Nat Rev Drug Discov, 2018, 17(4): 261-279. DOI: 10.1038/nrd.2017.243.

WANG Z, MA W T, FU X X, et al . Development and applications of mRNA treatment based on lipid nanoparticles[J ] . Biotechnol Adv, 2023, 65: 108130. DOI: 10.1016/j.biotechadv.2023.108130.

PATTIPEILUHU R, ARIAS-ALPIZAR G, BASHA G, et al . Anionic lipid nanoparticles preferentially deliver mRNA to the hepatic reticuloendothelial system[J ] . Adv Mater, 2022, 34(16): e2201095. DOI: 10.1002/adma.202201095.

LU B L, WILLIAMS G M, VERDON D J, et al . Synthesis and evaluation of novel TLR2 agonists as potential adjuvants for cancer vaccines[J ] . J Med Chem, 2020, 63(5): 2282-2291. DOI: 10.1021/acs.jmedchem.9b01044.

GAHÉRY-SÉGARD H, PIALOUX G, CHARMETEAU B, et al . Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine[J ] . J Virol, 2000, 74(4): 1694-1703. DOI: 10.1128/jvi.74.4.1694-1703.2000.

XUE R Y, LIU C, WANG J Q, et al . Synthetic self-adjuvanted lipopeptide vaccines conferred protection against Helicobacter pylori infection[J ] . Adv Healthc Mater, 2023, 12(23): e2300085. DOI: 10.1002/adhm.202300085..

LI M, JIANG Y H, GONG T, et al . Intranasal vaccination against HIV-1 with adenoviral vector-based nano complex using synthetic TLR-4 agonist peptide as adjuvant[J ] . Mol Pharm, 2016, 13(3): 885-894. DOI: 10.1021/acs.molpharmaceut.5b00802.

PHARES T W, KOTRAIAH V, KARUNARATHNE D S, et al . A peptide-based PD1 antagonist enhances T-cell priming and efficacy of a prophylactic malaria vaccine and promotes survival in a lethal malaria model[J ] . Front Immunol, 2020, 11: 1377. DOI: 10.3389/fimmu.2020.01377.

GU Y Z, YANG J Y, HE C, et al . Incorporation of a Toll-like receptor 2/6 agonist potentiates mRNA vaccines against cancer and infectious diseases[J ] . Signal Transduct Target Ther, 2023, 8: 273. DOI: 10.1038/s41392-023-01479-4.

KAYESH M E H, KOHARA M, TSUKIYAMA-KOHARA K. An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants[J]. Viruses, 2021, 13(11): 2302. DOI: 10.3390/v13112302.

ZHANG G, TANG T Y, CHEN Y F, et al . mRNA vaccines in disease prevention and treatment[J ] . Signal Transduct Target Ther, 2023, 8: 365. DOI: 10.1038/s41392-023-01579-1.

TOCKARY T A, ABBASI S, MATSUI-MASAI M, et al . Comb-structured mRNA vaccine tethered with short double-stranded RNA adjuvants maximizes cellular immunity for cancer treatment[J ] . Proc Natl Acad Sci U S A, 2023, 120(29): e2214320120. DOI: 10.1073/pnas.2214320120.

ZHANG R, TANG L, TIAN Y M, et al . Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens[J ] . Biomaterials, 2020, 241: 119852. DOI: 10.1016/j.biomaterials.2020.119852.

ALBERTSEN C H, KULKARNI J A, WITZIGMANN D, et al . The role of lipid components in lipid nanoparticles for vaccines and gene therapy[J ] . Adv Drug Deliv Rev, 2022, 188: 114416. DOI: 10.1016/j.addr.2022.114416.

KULKARNI J A, WITZIGMANN D, LEUNG J, et al . On the role of helper lipids in lipid nanoparticle formulations of siRNA[J ] . Nanoscale, 2019, 11(45): 21733-21739. DOI: 10.1039/C9NR09347H.

KULKARNI J A, MYHRE J L, CHEN S, et al . Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA[J ] . Nanomed Nanotechnol Biol Med, 2017, 13(4): 1377-1387. DOI: 10.1016/j.nano.2016.12.014..

SHI D, TOYONAGA S, ANDERSON D G. In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles[J ] . Nano Lett, 2023, 23(7): 2938-2944. DOI: 10.1021/acs.nanolett.3c00304..

KAUR A, PIPLANI S, KAUSHIK D, et al . Stereoisomeric Pam 2 CS based TLR2 agonists: synthesis, structural modelling and activity as vaccine adjuvants[J ] . RSC Med Chem, 2022, 13(5): 622-637. DOI: 10.1039/d1md00372k..

LIU H, ZHAO Z, ZHANG L, et al . Discovery of low-molecular weight anti-PD-L1 peptides for cancer Immunother[J ] . J Immunother Cancer, 2019, 7(1): 270. DOI: 10.1186/s40425-019-0705-y.

CHEN T K, LI Q, LIU Z L, et al . Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: a new choice for immunotherapy?[J ] . Eur J Med Chem, 2019, 161: 378-398. DOI: 10.1016/j.ejmech.2018.10.044.

SHANMUGAM A, RAJORIA S, GEORGE A L, et al . Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants[J ] . PLoS One, 2012, 7(2): e30839. DOI: 10.1371/journal.pone.0030839.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Immune-enhancing effect and mechanism of natural plant-derived immunostimulatory molecule ophiopogonin

Current status and prospect for development of COVID-19 vaccine adjuvants

Development of mucosal vaccine via respiratory tract based on mRNA-peptide-poloxamine nanoparticles

Related Author

CHI Yu

LI Guocheng

CHENG Hao

DENG Yan

WEI Jing

ZHU Ji

GAO Yingying

LI Haibo

Related Institution

Department of Microbiology and Biochemical Pharmacy， National Engineering Technology Research Center for Immune Biological Products， Faculty of Pharmacy and Laboratory Medicine， Army Medical University（Third Military Medical University）

Banan Hospital Affiliated to Chongqing Medical University

Clinical Medical School， Jiamusi University

Department of Pathogenic Biology， College of Basic Medical Sciences， Army Medical University （Third Military Medical University）

Department of Microbiology and Biochemical Pharmacy， National Engineering Research Center of Immunological Products， Faculty of Pharmacy and Laboratory Medicine， Army Medical University （Third Military Medical University）

⁰